Cue Biopharma, Inc. (CUE)
NASDAQ: CUE · Real-Time Price · USD
0.8250
+0.0423 (5.40%)
Apr 23, 2025, 4:00 PM EDT - Market closed

Company Description

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States.

Its lead drug product candidate is the CUE-401, a novel approach to induce and expand antigen specific Tregs for regulating disease causing autoreactive Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells.

The company also develops CUE-101, which is in phase 1b clinical trial to treat HPV+ recurrent metastatic, or head and neck squamous cell carcinoma in second line, and beyond patients as a monotherapy, as well as in phase 1b clinical trial for the treatment of head and neck squamous cell carcinoma as a first line, therapy in combination with standard of care KEYTRUDA; and CUE-102, which is in phase 1b clinical trial as a monotherapy in late line recurrent metastatic WT1+ colorectal, gastric, ovarian, and pancreatic cancer.

It has collaboration agreements with LG Chem, Ltd. for the development of CUE-101 and CUE-102 Immuno-STATs; collaboration and option agreement with Ono Pharmaceutical Co., Ltd to development and commercialization rights for CUE-401; and license agreement with Albert Einstein College of Medicine.

The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016.

Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Cue Biopharma, Inc.
Cue Biopharma logo
Country United States
Founded 2014
IPO Date Jan 2, 2018
Industry Biotechnology
Sector Healthcare
Employees 41
CEO Daniel Passeri

Contact Details

Address:
40 Guest Street
Boston, Massachusetts 02135
United States
Phone 617 949 2680
Website cuebiopharma.com

Stock Details

Ticker Symbol CUE
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001645460
CUSIP Number 22978P106
ISIN Number US22978P1066
Employer ID 47-3324577
SIC Code 2834

Key Executives

Name Position
Daniel R. Passeri J.D., M.Sc. Chief Executive Officer and Director
Kerri-Ann Millar CPA Chief Financial Officer
Dr. Ronald D. Seidel III, Ph.D. Co-Founder
Dr. Rodolfo J. Chaparro Ph.D. Co-Founder and Senior Advisor
Dr. Steven C. Almo Ph.D. Co-Founder and Chairman of Scientific and Clinical Advisory Board
Colin G. Sandercock J.D., MSE Senior Vice President, General Counsel and Secretary
Dr. Matteo Levisetti M.D. Chief Medical Officer
Lucinda Warren Chief Business Officer
Dr. Daniel G. Baker M.D., Ph.D. Interim Chief Development Officer

Latest SEC Filings

Date Type Title
Apr 15, 2025 8-K Current Report
Apr 15, 2025 424B5 Filing
Apr 14, 2025 424B5 Filing
Apr 14, 2025 8-K Current Report
Apr 14, 2025 PRE 14A Other preliminary proxy statements
Mar 31, 2025 S-8 Securities to be offered to employees in employee benefit plans
Mar 31, 2025 8-K Current Report
Mar 31, 2025 10-K Annual Report
Mar 21, 2025 SCHEDULE 13G/A Filing
Mar 12, 2025 8-K Current Report